查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016446

專業學名藥市場報告：按給藥途徑、適應症、分銷管道和地區分類（2026-2034 年）

Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球專業非專利市場規模達892億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,876億美元，2026年至2034年的複合年成長率（CAGR）為8.36%。推動市場成長的因素眾多，包括旨在整合能力、資源和市場佔有率的策略聯盟日益增多，線上藥局和遠端醫療平台的蓬勃發展，以及有利的政府政策。

特效法非專利是指價格昂貴的品牌特效藥的非專利藥版本。這些藥物用於治療癌症、類風濕性關節炎、多發性硬化症和愛滋病等複雜慢性疾病。它們與傳統生物製藥，需要特殊的處理和給藥方式（通常為注射劑），並且透過有限的分銷網路銷售。由於涉及的分子結構複雜且生產流程先進，特效法學名藥的研發面臨獨特的挑戰。因此，其核准流程可能比傳統學名藥更為嚴格。此外，非專利在醫療保健領域非專利巨大的潛力。它們在以更低的成本為患者提供必要的治療的同時，也減輕了醫療保健系統的經濟負擔。

先進分銷管道（例如線上藥局和遠端醫療平台）的發展也推動了專科學名藥市場的成長。這些管道方便了患者取得藥品，確保偏遠地區的患者也能獲得所需的藥物。此外，政府醫療保健計劃和私人保險公司也不斷尋求控制醫療成本飆升的策略。強調使用學名藥，尤其是專科學名藥，是這些關鍵策略之一。因此，許多政府和保險公司現在鼓勵或強制要求在有條件的情況下使用學名藥，從而刺激了需求。此外，由於價格實惠，專科非專利在許多地區正成為首選，使更多人能夠獲得必要的治療。因此，這極大地支撐了市場。另外，針對更細分和專業疾病的非專利的生產也促進了市場發展。此外，旨在利用合作夥伴公司的能力、資源和市場地位的策略聯盟也提振了市場前景。

專業非專利市場的趨勢與促進因素：

對價格合理的醫療保健解決方案的需求日益成長

隨著世界人口成長和非傳染性疾病（NCDs）負擔加重，人們對價格合理的醫療保健解決方案的需求日益成長。專業非專利產業在滿足這一需求方面具有獨特的優勢。專業非專利與品牌藥具有生物等效性，能夠以更低的成本為患者和醫療保健系統提供與創新藥物相同的療效。此外，包括日本、美國和許多歐洲國家在內的已開發國家人口老化加劇，慢性病的發生率不斷上升。這些疾病通常需要長期且複雜的治療方案，這會對個人和國家醫療保健系統造成沉重的經濟負擔。在開發中國家，中產階級的壯大及其對先進醫療保健解決方案日益成長的需求也給現有的醫療基礎設施帶來了壓力。

品牌藥品專利到期

推動專業學名藥產業發展的最重要因素之一是品牌藥專利到期。一旦專利失效，其他生產商就可以生產和銷售這些藥物的非專利藥版本。由於學名藥的研發成本通常低於新藥，因此可以在保持療效的同時，以更實惠的價格提供學名藥。每年，銷售額達數十億美元的藥物都會失去專利保護。這為專業非專利生產商提供了一個進入成熟市場和現有消費群的絕佳機會。因此，這些藥物的可近性得到改善，使更多人受益，尤其是中低收入家庭，並對市場產生正面影響。

藥物研發中的技術進步

專業學名藥產業正與整個製藥產業同步發展。近年來，藥物研發和生產技術的進步使得生產更複雜的學名藥（例如生物相似藥）成為可能，而這些藥物先前難以生產。此外，人工智慧和先進分析技術等工具正在簡化這些藥物的研發流程。這意味著專業學名藥生產商現在能夠應對比以往任何時候都更廣泛的疾病和症狀。而且，生產流程的創新確保了這些藥物的品質穩定，並符合全球監管機構制定的嚴格標準。因此，這正在推動市場發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：全球特藥非專利市場：引言

第5章：為什麼專業學名藥如此盈利？

第6章：全球特藥學名藥市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依給藥途徑
  • 市場區隔：依指標
  • 市場區隔：依分銷通路分類
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
  • 價值鏈分析
  • 波特五力分析
  • 關鍵市場促進因素與成功因素

第7章 市場區隔：依給藥途徑

  • 注射藥物
  • 口服
  • 其他

第8章 市場區隔：依適應症分類

  • 腫瘤學
  • 自體免疫疾病
  • 感染疾病
  • 其他

第9章 市場區隔：依分銷通路分類

  • 零售藥房
  • 專科藥房
  • 醫院藥房

第10章 市場區隔：依地區分類

  • 北美洲
    • 市場概覽
    • 市場表現
    • 市場細分：按國家/地區
      • 美國
      • 加拿大
    • 市場預測
  • 歐洲
    • 市場概覽
    • 市場表現
    • 市場細分：按國家/地區
      • 義大利
      • 德國
      • 法國
      • 英國
      • 西班牙
    • 市場預測
  • 亞太地區
    • 市場概覽
    • 市場表現
    • 市場細分：按國家/地區
      • 日本
      • 中國
      • 印度
      • 韓國
    • 市場預測
  • 拉丁美洲
    • 市場概覽
    • 市場表現
    • 市場細分：按國家/地區
      • 巴西
      • 墨西哥
    • 市場預測
  • 中東和非洲
    • 市場概覽
    • 市場表現
    • 市場預測

第11章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amneal Pharmaceuticals LLC
    • Apotex Corp.
    • Bausch Health Companies Inc.
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc.
    • Hikma Pharmaceuticals PLC
    • Mallinckrodt Pharmaceuticals
    • Sandoz Group AG
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: SR112026A1219

The global specialty generics market size reached USD 89.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 187.6 Billion by 2034, exhibiting a growth rate (CAGR) of 8.36% during 2026-2034. There are various factors that are driving the market, which include rising number of strategic collaborations aiming to leverage the capabilities, resources, and market presence, the evolution of online pharmacies and telemedicine platforms, and favorable government initiatives.

Specialty generics refer to generic versions of high-cost, brand-name specialty drugs. These medications are used to treat complex, chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and HIV. They differ from traditional generics in that they are typically biologic-based, require special handling and administration often injectables, and are often distributed through limited networks. The development of specialty generics presents unique challenges due to the intricate nature of the molecules involved and the complex processes used in their manufacturing. As a result, regulatory pathways for their approval can be more stringent compared to conventional generic drugs. In addition, specialty generics hold immense potential in healthcare. They offer patients access to vital treatments at a reduced cost, while also alleviating the financial burden on healthcare systems.

The evolution of advanced distribution channels, such as online pharmacies and telemedicine platforms, has also propelled the growth of the specialty generics market. These channels facilitate easy access to medications, ensuring patients in even remote locations can obtain the drugs they need. Along with this, government healthcare programs and private payers are continuously seeking strategies to contain escalating healthcare costs. Emphasizing the use of generic drugs, especially specialty generics, is a primary strategy. Therefore, several governments and insurance companies now incentivize or mandate the prescription of generics where available, thereby driving demand. In addition, specialty generics, being more affordably priced, have become the preferred choice for many in regions, ensuring essential treatments are within reach of larger segments of the population. Thus, this is significantly supporting the market. Apart from this, the production of generics for more niche, and specialized conditions is contributing to the market. Moreover, strategic collaborations aiming to leverage the capabilities, resources, and market presence of partnering entities are creating a positive market outlook.

Specialty Generics Market Trends/Drivers:

Increasing Demand for Affordable Healthcare Solutions

As the global population continues to rise and the burden of non-communicable diseases (NCDs) expands, there's a significant push to provide affordable healthcare solutions. The specialty generics industry is uniquely poised to address this demand. Specialty generics, which are bioequivalent versions of brand-name drugs, offer patients and healthcare systems the therapeutic efficacy of innovative medicines but at a reduced cost. Additionally, aging populations in various developed countries, such as Japan, the United States, and numerous European nations, are leading to an increased incidence of chronic diseases. These conditions often require prolonged and complex treatment regimens, which can be financially taxing for both individuals and national healthcare systems. Furthermore, in developing nations, the expansion of middle-class populations and their demand for advanced healthcare solutions is putting a strain on existing infrastructures.

Patent Expirations of Branded Drugs

One of the most significant drivers of the specialty generics industry is the expiration of patents for branded drugs. When patents expire, it opens the door for other manufacturers to produce and market generic versions of those medications. Given that research and development (R&D) costs for generics are typically lower than for novel drugs, these medications can be priced more affordably while maintaining therapeutic efficacy. Each year, drugs with billions of dollars in annual sales lose patent protection. This presents a golden opportunity for specialty generic manufacturers to tap into established markets with a ready consumer base. Thus, the accessibility of these medications then benefits the wider population, especially those in low-to-middle-income households, positively influencing the market.

Technological Advancements in Drug Development

The specialty generics industry is evolving with the broader pharmaceutical sector. Along with this, recent technological advancements in drug development and manufacturing are enabling the production of more complex generics, such as biosimilars, which were previously challenging to produce. In addition, tools, such as artificial intelligence and advanced analytical methodologies have streamlined the research and development (R&D) process for these drugs. This means that specialty generic manufacturers now address a broader range of diseases and conditions than ever before. Furthermore, innovations in manufacturing processes are ensuring that these drugs are produced with consistent quality, meeting the rigorous standards set by global regulatory bodies. As a result, it is also contributing to the market.

Specialty Generics Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with specialty generics market forecast at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on route of administration, indication, and distribution channel.

Breakup by Route of Administration:

  • Injectables
  • Oral
  • Others

Injectable dominates the market

The injectables route of administration has emerged as a significant market driver within the specialty generics industry. This growth can be attributed to the increasing prevalence of chronic diseases and complex medical conditions. Injectables offer advantages, including precise dosing and rapid onset of action, making them suitable for managing critical health conditions. In addition, the expiration of patents for certain branded biologics and specialty drugs has opened doors for generic manufacturers to enter the market with cost-effective alternatives. Moreover, the rising focus on research and development in the pharmaceutical sector has led to innovative injectable products with improved therapeutic outcomes. These market drivers collectively contribute to the growth and prominence of the injectables route of administration in the specialty generics industry.

On the contrary, the oral route of administration plays a pivotal role as a market driver within the specialty generics industry, due to the changing consumer preferences. Numerous patients prefer oral formulations due to ease of administration, eliminating the need for injections and reducing potential discomfort. Along with this, the vast array of chronic diseases and conditions requiring long-term treatment has contributed to the popularity of oral drugs.

Breakup by Indication:

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

Oncology dominates the market

The rising prevalence of cancer continues to rise globally, necessitating a constant demand for effective and affordable oncology treatments. With an increasing number of patients requiring long-term therapies, the accessibility and cost-effectiveness of specialty generics become essential in improving cancer care. In addition, the expiration of patents for several branded oncology drugs has opened opportunities for generic manufacturers to enter the market, offering more affordable alternatives without compromising on quality. Apart from this, advancements in research and technology have led to the development of innovative formulations and drug delivery systems, enhancing the efficacy and patient compliance of oncology generics. Moreover, government initiatives and policies aimed at reducing the burden of cancer by promoting generic drug usage have further propelled market growth.

On the other hand, the infectious diseases route of administration has emerged as a crucial market driver within the specialty generics industry, influenced by the ongoing global burden of infectious diseases, including outbreaks and pandemics, has underscored the urgent need for effective and accessible treatment options.

Breakup by Distribution channel:

  • Retail Pharmacies
  • Specialty Pharmacies
  • Hospital Pharmacies

Retail pharmacies dominates the market

The retail pharmacies distribution channel plays a pivotal role as a market driver within the specialty generics industry, primarily influenced by the widespread presence of retail pharmacies ensuring convenient and accessible distribution of specialty generic medications to a broader patient base. As these pharmacies are typically located in various communities and neighborhoods, patients can easily access their prescribed medications without the need for specialized healthcare facilities. In addition, the rising prevalence of chronic diseases and the growing demand for long-term treatment options have amplified the significance of retail pharmacies in delivering specialty generics. Furthermore, the retail pharmacies' established relationships with healthcare providers allow for streamlined communication and collaboration, facilitating efficient prescription processing and patient care. As the demand for specialty generics continues to grow, retail pharmacies' essential role in distribution and patient support is set to reinforce the industry's expansion and accessibility to critical medications.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Europe
  • Italy
  • Germany
  • Spain
  • United Kingdom
  • France
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest specialty generics market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Italy, Germany, France, United Kingdom, and Spain); Asia Pacific (Japan, China, India, and South Korea); Latin America (Brazil, Mexico); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America region is driven by the increasing prevalence of chronic diseases and complex medical conditions. It is leading to a growing demand for specialized treatment options. Specialty generics, with their cost-effective alternatives to branded specialty drugs, have gained traction in managing these conditions effectively. Additionally, the expiration of patents for certain branded specialty medications has created opportunities for generic manufacturers to enter the market, providing patients with more affordable treatment options. In addition, favorable government policies and initiatives aimed at promoting the use of generic medications have supported the expansion of the specialty generics industry in North America. These policies encourage generic drug usage, leading to enhanced patient access and overall cost savings in the healthcare system. Moreover, advancements in research and development leading to the introduction of innovative specialty generics with improved therapeutic outcomes are positively influencing the market.

Competitive Landscape:

The global specialty generics market is experiencing significant growth due to the escalating investments in research and development to develop innovative formulations, drug delivery systems, and combination therapies to improve the efficacy and patient compliance of their products. Ensuring compliance with regulatory standards and obtaining necessary approvals from health authorities in various countries is a critical aspect for specialty generic companies to launch and market their products. Along with this, the expansion of product portfolios to cover a wider range of therapeutic areas, such as oncology, immunology, and rare diseases, to cater to diverse patient needs is positively influencing the market. Apart from this, companies are offering patient support programs that provide counseling, adherence assistance, and financial aid to patients, thereby improving patient outcomes and medication adherence. Furthermore, collaborating with pharmaceutical companies, research institutions, and healthcare organizations allows specialty generics companies to access new technologies is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.

Some of the key players in the market include:

  • Teva Pharmaceuticals Industries
  • Akorn, Inc.
  • Mylan N.V.
  • Mallinckrodt
  • Sandoz International GmbH
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals
  • Apotex Corp.
  • Endo International plc

Key Questions Answered in This Report

1. What is the size of the global specialty generics market?

2. What are the key factors driving the global specialty generics market?

3. What has been the impact of COVID-19 on the global specialty generics market?

4. What is the breakup of the global specialty generics market based on the route of administration?

5. What is the breakup of the global specialty generics market based on the indication?

6. What is the breakup of the global specialty generics market based on the distribution channel?

7. What are the key regions in the global specialty generics market?

8. Who are the key players/companies in the global specialty generics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Breakup by Route of Administration
  • 6.5 Market Breakup by Indication
  • 6.6 Market Breakup by Distribution Channel
  • 6.7 Market Breakup by Region
  • 6.8 Market Forecast
  • 6.9 SWOT Analysis
    • 6.9.1 Overview
    • 6.9.2 Strengths
    • 6.9.3 Weaknesses
    • 6.9.4 Opportunities
    • 6.9.5 Threats
  • 6.10 Value Chain Analysis
  • 6.11 Porters Five Forces Analysis
    • 6.11.1 Overview
    • 6.11.2 Bargaining Power of Buyers
    • 6.11.3 Bargaining Power of Suppliers
    • 6.11.4 Degree of Competition
    • 6.11.5 Threat of New Entrants
    • 6.11.6 Threat of Substitutes
  • 6.12 Key Market Drivers and Success Factors

7 Market Breakup by Route of Administration

  • 7.1 Injectable
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialty Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Hospital Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Overview
    • 10.1.2 Market Performance
    • 10.1.3 Market Breakup by Country
      • 10.1.3.1 United States
        • 10.1.3.1.1 Market Trends
        • 10.1.3.1.2 Market Forecast
      • 10.1.3.2 Canada
        • 10.1.3.2.1 Market Trends
        • 10.1.3.2.2 Market Forecast
    • 10.1.4 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Overview
    • 10.2.2 Market Performance
    • 10.2.3 Market Breakup by Country
      • 10.2.3.1 Italy
        • 10.2.3.1.1 Market Trends
        • 10.2.3.1.2 Market Forecast
      • 10.2.3.2 Germany
        • 10.2.3.2.1 Market Trends
        • 10.2.3.2.2 Market Forecast
      • 10.2.3.3 France
        • 10.2.3.3.1 Market Trends
        • 10.2.3.3.2 Market Forecast
      • 10.2.3.4 United Kingdom
        • 10.2.3.4.1 Market Trends
        • 10.2.3.4.2 Market Forecast
      • 10.2.3.5 Spain
        • 10.2.3.5.1 Market Trends
        • 10.2.3.5.2 Market Forecast
    • 10.2.4 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Overview
    • 10.3.2 Market Performance
    • 10.3.3 Market Breakup by Country
      • 10.3.3.1 Japan
        • 10.3.3.1.1 Market Trends
        • 10.3.3.1.2 Market Forecast
      • 10.3.3.2 China
        • 10.3.3.2.1 Market Trends
        • 10.3.3.2.2 Market Forecast
      • 10.3.3.3 India
        • 10.3.3.3.1 Market Trends
        • 10.3.3.3.2 Market Forecast
      • 10.3.3.4 South Korea
        • 10.3.3.4.1 Market Trends
        • 10.3.3.4.2 Market Forecast
    • 10.3.4 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Market Overview
    • 10.4.2 Market Performance
    • 10.4.3 Market Breakup by Country
      • 10.4.3.1 Brazil
        • 10.4.3.1.1 Market Trends
        • 10.4.3.1.2 Market Forecast
      • 10.4.3.2 Mexico
        • 10.4.3.2.1 Market Trends
        • 10.4.3.2.2 Market Forecast
    • 10.4.4 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Overview
    • 10.5.2 Market Performance
    • 10.5.3 Market Forecast

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 Amneal Pharmaceuticals LLC
    • 11.3.2 Apotex Corp.
    • 11.3.3 Bausch Health Companies Inc.
    • 11.3.4 Dr. Reddy's Laboratories Ltd
    • 11.3.5 Endo International plc.
    • 11.3.6 Hikma Pharmaceuticals PLC
    • 11.3.7 Mallinckrodt Pharmaceuticals
    • 11.3.8 Sandoz Group AG
    • 11.3.9 Sun Pharmaceutical Industries Ltd.
    • 11.3.10 Teva Pharmaceutical Industries Ltd.
    • 11.3.11 Viatris Inc.

List of Figures

  • Figure 1: Global: Specialty Generics Market: Major Drivers and Challenges
  • Figure 2: Global: Specialty Generics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Specialty Generics Market: Breakup by Route of Administration (in %), 2025
  • Figure 4: Global: Specialty Generics Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Specialty Generics Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Specialty Generics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Specialty Generics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Specialty Generics Industry: SWOT Analysis
  • Figure 9: Global: Specialty Generics Industry: Value Chain Analysis
  • Figure 10: Global: Specialty Generics Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Specialty Generics Market (Administration through Injectables): Sales Value (in Billion USD), 2020 & 2025
  • Figure 12: Global: Specialty Generics Market (Administration through Injectables) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 13: Global: Specialty Generics Market (Oral Administration): Sales Value (in Billion USD), 2020 & 2025
  • Figure 14: Global: Specialty Generics Market (Oral Administration) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 15: Global: Specialty Generics Market (Other Routes of Administration): Sales Value (in Billion USD), 2020 & 2025
  • Figure 16: Global: Specialty Generics Market (Other Routes of Administration) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 17: Global: Specialty Generics Market (Oncology): Sales Value (in Billion USD), 2020 & 2025
  • Figure 18: Global: Specialty Generics Market (Oncology) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 19: Global: Specialty Generics Market (Autoimmune Diseases): Sales Value (in Billion USD), 2020 & 2025
  • Figure 20: Global: Specialty Generics Market (Autoimmune Diseases) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 21: Global: Specialty Generics Market (Infectious Diseases): Sales Value (in Billion USD), 2020 & 2025
  • Figure 22: Global: Specialty Generics Market (Infectious Diseases) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 23: Global: Specialty Generics Market (Other Indications): Sales Value (in Billion USD), 2020 & 2025
  • Figure 24: Global: Specialty Generics Market (Other Indications) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 25: Global: Specialty Generics Market: Sales Through Retail Pharmacies (in Billion USD), 2020 & 2025
  • Figure 26: Global: Specialty Generics Market Forecast: Sales Through Retail Pharmacies (in Billion USD), 2026-2034
  • Figure 27: Global: Specialty Generics Market: Sales Through Specialty Pharmacies (in Billion USD), 2020 & 2025
  • Figure 28: Global: Specialty Generics Market Forecast: Sales Through Specialty Pharmacies (in Billion USD), 2026-2034
  • Figure 29: Global: Specialty Generics Market: Sales Through Hospital Pharmacies (in Billion USD), 2020 & 2025
  • Figure 30: Global: Specialty Generics Market Forecast: Sales Through Hospital Pharmacies (in Billion USD), 2026-2034
  • Figure 31: North America: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Europe: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Europe: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Italy: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Italy: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Germany: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Germany: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: France: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: France: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: United Kingdom: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: United Kingdom: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Spain: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Spain: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Asia Pacific: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Asia Pacific: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Japan: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Japan: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: China: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: China: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: India: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: India: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: South Korea: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: South Korea: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Latin America: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Latin America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Brazil: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Brazil: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Mexico: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Mexico: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Middle East and Africa: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Middle East and Africa: Specialty Generics Market: Breakup by Country (in %), 2025
  • Figure 67: Middle East and Africa: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Specialty Generics Market Forecast: Breakup by Route of Administration (in Billion USD), 2026-2034
  • Table 3: Global: Specialty Generics Market Forecast: Breakup by Indication (in Billion USD), 2026-2034
  • Table 4: Global: Specialty Generics Market Forecast: Breakup by Distribution Channel (in Billion USD), 2026-2034
  • Table 5: Global: Specialty Generics Market Forecast: Breakup by Region (in Billion USD), 2026-2034
  • Table 6: North America: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 7: Europe: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 8: Asia Pacific: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 9: Latin America: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 10: Middle East and Africa: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 11: Global: Specialty Generics Market Structure
  • Table 12: Global: Specialty Generics Market: Key Players